Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

53 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy of adjuvant capecitabine in residual triple negative breast cancer: a multicenter observational Turkish Oncology Group (TOG) study.
Taşçı EŞ, Kutlu Y, Ölmez ÖF, Mutlu AU, Gündoğdu Y, Seyyar M, Şahin E, Çabuk D, Majidova N, Uğurlu İ, Demirci A, Aydın D, Çavdar E, Bayram S, Yıldırım N, Karataş F, Eryılmaz MK, Çağlayan D, Menekşe S, Kut E, Arak H, Keser M, Sunar V, Perkin P, Şakalar T, Oyan B, Sönmez Ö, Özer L, Yıldız İ. Taşçı EŞ, et al. Among authors: kut e. Expert Opin Pharmacother. 2024 Mar;25(4):477-484. doi: 10.1080/14656566.2024.2337261. Epub 2024 Apr 3. Expert Opin Pharmacother. 2024. PMID: 38568074
Does primary tumor localization has prognostic importance in seminoma patients?: Turkish Oncology Group Study.
Yildiz B, Kucukarda A, Gokyer A, Gokcen Demiray A, Paydas S, Pinar Aral I, Gumusay O, Bilici A, Akdeniz N, Bahceci A, Demir H, Esin E, Üyeturk U, Nihat Okten I, Erturk I, Turk HM, Topaloglu US, Basoglu T, Serdar Turhal N, Yesil Cinkir H, Menekse S, Cakmak Y, Urun Y, Acar R, Kut E, Dal P, Sakalar T, Halit Aktepe O, Karadurmus N, Bilici A. Yildiz B, et al. Among authors: kut e. J BUON. 2020 Mar-Apr;25(2):1130-1135. J BUON. 2020. PMID: 32521916 Free article.
Real-life comparison of the afatinib and first-generation tyrosine kinase inhibitors in nonsmall cell lung cancer harboring EGFR exon 19 deletion: a Turk Oncology Group (TOG) study.
Bilgin B, Sendur MAN, Yucel S, Celik E, Ozyukseler DT, Ayhan M, Basoglu T, Ilhan A, Akdeniz N, Gulmez A, Dogan I, Aktas BY, Gurbuz M, Koca S, Paydas S, Tatli AM, Cinkir HY, Alan O, Erol C, Hizal M, Kut E, Menevse S, Sakalar T, Taskaynatan H, Deniz GI, Karaagac M, Avci O, Sen E, Karatas F, Akinci MB, Dede DS, Demir A, Demirkazık A, Oksuzoglu B, Kilickap S, Yumuk F, Yalcin B. Bilgin B, et al. Among authors: kut e. J Cancer Res Clin Oncol. 2021 Jul;147(7):2145-2152. doi: 10.1007/s00432-020-03501-6. Epub 2021 Jan 12. J Cancer Res Clin Oncol. 2021. PMID: 33433657
Real-life comparison of afatinib and erlotinib in non-small cell lung cancer with rare EGFR exon 18 and exon 20 mutations: a Turkish Oncology Group (TOG) study.
Gursoy P, Tatli AM, Erdem D, Goker E, Celik E, Demirci NS, Sakin A, Atci MM, Bayram E, Telli TA, Bilgin B, Bilici A, Akangunduz B, Balli S, Demirkazik A, Selçukbiricik F, Menekse S, Cavdar E, Ozturk A, Bekmez ET, Turhal S, Kilickap S, Yildirim HÇ, Oyan B, Aksoy A, Turkoz FP, Kut E, Katgi N, Sakalar T, Akyol M, Ellez Hİ, Topcu A, Erdoğan AP, Pilanci KN, Hedem E, Arak H, Akdeniz N, Alan Ö, Yapar B, Nart D, Yumuk PF. Gursoy P, et al. Among authors: kut e. J Cancer Res Clin Oncol. 2023 Feb;149(2):865-875. doi: 10.1007/s00432-022-03984-5. Epub 2022 Apr 5. J Cancer Res Clin Oncol. 2023. PMID: 35381885
First-line treatment of patients with HER2-positive metastatic gastric and gastroesophageal junction cancer.
Aktürk Esen S, Ergun Y, Erol C, Arikan R, Er MM, Atci MM, Topçu A, Uçar G, Akagündüz B, Aykan MB, Özen M, Baytemur NK, Özçelik M, Şahin E, Güven D, Menekşe S, Ak N, Teker F, Kut E, Şakalar T, Alan Ö, Kaçan T, Turhal NS, Kiliçkap S, Türker S, Şendur MAN, Köstek O, Karaağaç M, Sakin A, Türk HM, Çağlayan D, Cihan Ş, Açikgöz Y, Uncu D. Aktürk Esen S, et al. Among authors: kut e. Bosn J Basic Med Sci. 2022 Sep 16;22(5):818-825. doi: 10.17305/bjbms.2021.7069. Bosn J Basic Med Sci. 2022. PMID: 35460397 Free PMC article.
Efficacy and safety of folfiri plus aflibercept in second-line treatment of metastatic colorectal cancer: Real-life data from Turkish oncology group.
Erol C, Sendur MAN, Bilgetekin I, Garbioglu DB, Hamdard J, Akbas S, Hizal M, Arslan C, Sevinc A, Kucukarda A, Erdem D, Kahraman S, Cakir E, Demirkiran A, On S, Dogan I, Erdogan AP, Koca S, Kubilay P, Eren OO, Cilbir E, Celik E, Araz M, Ozyukseler DT, Yildirim ME, Bahceci A, Taskaynatan H, Oyman A, Deniz GI, Menekse S, Kut E, Gulmez A, Sakin A, Nayir E, Acar R, Sen E, Inal A, Turhal S, Kaya AO, Paydas S, Tastekin D, Hacibekiroglu I, Cincin I, Bilici A, Mandel NM, Dede DS, Akinci MB, Oksuzoglu B, Uncu D, Yalcin B, Artac M. Erol C, et al. Among authors: kut e. J Cancer Res Ther. 2022 Dec;18(12 Suppl 2):S347-S353. doi: 10.4103/jcrt.jcrt_1104_21. J Cancer Res Ther. 2022. PMID: 36510987 Free article. Clinical Trial.
Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy.
Karacin C, Oksuzoglu B, Demirci A, Keskinkılıç M, Baytemür NK, Yılmaz F, Selvi O, Erdem D, Avşar E, Paksoy N, Demir N, Göksu SS, Türker S, Bayram E, Çelebi A, Yılmaz H, Kuzu ÖF, Kahraman S, Gökmen İ, Sakin A, Alkan A, Nayır E, Uğraklı M, Acar Ö, Ertürk İ, Demir H, Aslan F, Sönmez Ö, Korkmaz T, Celayir ÖM, Karadağ İ, Kayıkçıoğlu E, Şakalar T, Öktem İN, Eren T, Erul E, Mocan EE, Kalkan Z, Yıldırım N, Ergün Y, Akagündüz B, Karakaya S, Kut E, Teker F, Demirel BÇ, Karaboyun K, Almuradova E, Ünal OÜ, Oyman A, Işık D, Okutur K, Öztosun B, Gülbağcı BB, Kalender ME, Şahin E, Seyyar M, Özdemir Ö, Selçukbiricik F, Kanıtez M, Dede İ, Gümüş M, Gökmen E, Yaren A, Menekşe S, Ebinç S, Aksoy S, İmamoğlu Gİ, Altınbaş M, Çetin B, Uluç BO, Er Ö, Karadurmuş N, Erdoğan AP, Artaç M, Tanrıverdi Ö, Çiçin İ, Şendur MAN, Oktay E, Bayoğlu İV, Paydaş S, Aydıner A, Salim DK, Geredeli Ç, Yavuzşen T, Doğan M, Hacıbekiroğlu İ. Karacin C, et al. Among authors: kut e. BMC Cancer. 2023 Feb 10;23(1):136. doi: 10.1186/s12885-023-10609-8. BMC Cancer. 2023. PMID: 36765293 Free PMC article.
Correction: Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy.
Karacin C, Oksuzoglu B, Demirci A, Keskinkılıç M, Baytemür NK, Yılmaz F, Selvi O, Erdem D, Avşar E, Paksoy N, Demir N, Göksu SS, Türker S, Bayram E, Çelebi A, Yılmaz H, Kuzu ÖF, Kahraman S, Gökmen İ, Sakin A, Alkan A, Nayır E, Uğraklı M, Acar Ö, Ertürk İ, Demir H, Aslan F, Sönmez Ö, Korkmaz T, Celayir ÖM, Karadağ İ, Kayıkçıoğlu E, Şakalar T, Öktem İN, Eren T, Erul E, Mocan EE, Kalkan Z, Yıldırım N, Ergün Y, Akagündüz B, Karakaya S, Kut E, Teker F, Demirel BÇ, Karaboyun K, Almuradova E, Ünal OÜ, Oyman A, Işık D, Okutur K, Öztosun B, Gülbağcı BB, Kalender ME, Şahin E, Seyyar M, Özdemir Ö, Selçukbiricik F, Kanıtez M, Dede İ, Gümüş M, Gökmen E, Yaren A, Menekşe S, Ebinç S, Aksoy S, İmamoğlu Gİ, Altınbaş M, Çetin B, Uluç BO, Er Ö, Karadurmuş N, Erdoğan AP, Artaç M, Tanrıverdi Ö, Çiçin İ, Şendur MAN, Oktay E, Bayoğlu İV, Paydaş S, Aydıner A, Salim DK, Geredeli Ç, Yavuzşen T, Doğan M, Hacıbekiroğlu İ. Karacin C, et al. Among authors: kut e. BMC Cancer. 2023 Feb 27;23(1):192. doi: 10.1186/s12885-023-10662-3. BMC Cancer. 2023. PMID: 36849943 Free PMC article. No abstract available.
53 results